Detalhe da pesquisa
1.
Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
Eur Heart J
; 43(27): 2622-2632, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608040
2.
Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis.
J Am Heart Assoc
; : e034723, 2024 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38904242
3.
Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.
ESC Heart Fail
; 11(3): 1707-1719, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38444090
4.
Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study.
Amyloid
; 30(4): 407-415, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37377439
5.
Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis.
Mayo Clin Proc
; 98(1): 48-59, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36464537
6.
Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis.
Front Cardiovasc Med
; 10: 1124660, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36998975
7.
Prevalence and determinants of iron deficiency in cardiac amyloidosis.
ESC Heart Fail
; 9(2): 1314-1327, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35128833
8.
Evaluation of a new ELISA assay for monoclonal free-light chain detection in patients with cardiac amyloidosis.
EJHaem
; 3(3): 828-837, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36051065
9.
Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis.
Transplant Direct
; 8(7): e1323, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35747521
10.
Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival.
Amyloid
; 29(2): 79-91, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35114877
11.
Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
JACC CardioOncol
; 4(4): 442-454, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36444226
12.
The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials.
JACC Heart Fail
; 9(3): 169-178, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33549560
13.
Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis.
ESC Heart Fail
; 8(2): 1656-1665, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33354901
14.
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment.
J Clin Med
; 10(21)2021 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34768388
15.
Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation.
J Clin Med
; 10(21)2021 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34768408
16.
Assessing Cardiac Amyloidosis Subtypes by Unsupervised Phenotype Clustering Analysis.
J Am Coll Cardiol
; 78(22): 2177-2192, 2021 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34823661
17.
Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
PLoS One
; 16(9): e0257189, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34525116
18.
History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis.
ESC Heart Fail
; 8(6): 5501-5512, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34714605
19.
Epidemiological characteristics and therapeutic management of patients with chronic heart failure who use smartphones: Potential impact of a dedicated smartphone application (report from the OFICSel study).
Arch Cardiovasc Dis
; 114(1): 51-58, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32868257
20.
Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
Eur J Heart Fail
; 23(2): 264-274, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33094885